



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

NGUYEN *et al.*

Appl. No. 09/227,881

Filed: January 11, 1999

For: **Nucleic Acids, Kits and Methods  
for the Diagnosis, Prognosis and  
Treatment of Glaucoma and  
Related Disorders**

Art Unit: 1635

Examiner: Schultz

Atty. Docket: 16491.066

**Amendment and Reply**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants submit the following amendments and remarks in response to the interview of April 26, 2005.

It is not believed that extensions of time are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 50-1824 referencing matter number 16491.066.

## **INTRODUCTORY COMMENTS**

Applicants thank Examiner J. Douglas Schultz and Supervisory Patent Examiner Andrew Wang for extending the courtesy of a personal interview on April 26, 2005, and for their helpful suggestions. In consideration of that Interview Applicants submit the following amendments, and terminal disclaimer. Applicants respectfully submit that application is in condition for allowance and earnestly solicit a notice of allowance at the earliest possible time.